Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.
Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M. Ronco G, et al. Among authors: naldoni c. BMJ. 2007 Jul 7;335(7609):28. doi: 10.1136/bmj.39196.740995.BE. Epub 2007 May 21. BMJ. 2007. PMID: 17517761 Free PMC article. Clinical Trial.
Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.
Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group. Gillio-Tos A, et al. J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26. J Clin Microbiol. 2013. PMID: 23804385 Free PMC article. Clinical Trial.
Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial.
Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer screening Working Group. Ronco G, et al. Among authors: naldoni c. Lancet Oncol. 2006 Jul;7(7):547-55. doi: 10.1016/S1470-2045(06)70731-8. Lancet Oncol. 2006. PMID: 16814206 Clinical Trial.
HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology.
Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A, Gillio-Tos A, Giubilato P, Naldoni C, Polla E, Iossa A, Zorzi M, Confortini M, Giorgi-Rossi P; NTCC working group. Ronco G, et al. Among authors: naldoni c. Eur J Cancer. 2007 Feb;43(3):476-80. doi: 10.1016/j.ejca.2006.11.013. Epub 2007 Jan 12. Eur J Cancer. 2007. PMID: 17223540
The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment.
Ronco G, Brezzi S, Carozzi F, Dalla Palma P, Giorgi-Rossi P, Minucci D, Naldoni C, Segnan N, Zappa M, Zorzi M, Cuzick J; NTCC study group. Ronco G, et al. Among authors: naldoni c. Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S230-2. doi: 10.1016/j.ygyno.2007.07.021. Epub 2007 Sep 6. Gynecol Oncol. 2007. PMID: 17822751 Clinical Trial.
Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group. Ronco G, et al. Among authors: naldoni c. J Natl Cancer Inst. 2008 Apr 2;100(7):492-501. doi: 10.1093/jnci/djn065. Epub 2008 Mar 25. J Natl Cancer Inst. 2008. PMID: 18364502 Clinical Trial.
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies for Cervical Cancer screening (NTCC) Working Group. Ronco G, et al. Among authors: naldoni c. Lancet Oncol. 2010 Mar;11(3):249-57. doi: 10.1016/S1470-2045(09)70360-2. Epub 2010 Jan 18. Lancet Oncol. 2010. PMID: 20089449 Clinical Trial.
[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P. Ronco G, et al. Among authors: naldoni c. Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Epidemiol Prev. 2012. PMID: 22828243 Free article. Italian.
127 results